Innovent Biologics and Pfizer Forge $10.5 Billion Oncology Partnership

Innovent Biologics and Pfizer have entered into a major global strategic collaboration aimed at accelerating the development of next-generation oncology medicines, in a deal valued at up to $10.5 billion.

The agreement will focus on the research and development of 12 early-stage and de novo cancer therapies spanning antibody-drug conjugates (ADCs) and multispecific antibodies, reflecting growing industry demand for novel targeted cancer treatments and continued interest from multinational pharmaceutical companies in Chinese biotech innovation.

Under the terms of the collaboration, Innovent will receive an upfront payment of $650 million and will be eligible for up to $9.85 billion in development, regulatory and commercial milestone payments. The company may also receive tiered royalties on approved products, while select programmes will involve profit-sharing arrangements in the United States and Europe.

The partnership combines Innovent’s discovery and early clinical development capabilities with Pfizer’s global development infrastructure, regulatory expertise and commercial reach. Analysts have described the deal as one of the largest recent cross-border oncology partnerships involving a Chinese biotechnology company.

The collaboration spans 12 programmes, including eight Innovent-originated assets and four discovery-stage programmes proposed by Pfizer. The portfolio includes antibody-drug conjugates featuring differentiated payload technologies and multispecific antibodies designed to engage immune targets through novel mechanisms.

Innovent will lead development activities through Phase 1 clinical trials using its proprietary oncology discovery platform and early-stage development infrastructure. Pfizer will subsequently assume responsibility for later-stage global development.

Four programmes will be jointly developed globally, with both companies sharing development costs and co-commercialisation rights in the U.S. and Europe. Innovent will retain commercial rights in Greater China for those assets. Additional programmes will be licensed exclusively to Pfizer outside Greater China or globally, depending on the asset structure.

The agreement reflects increasing confidence among multinational pharmaceutical companies in China’s biotechnology sector, particularly in oncology, where Chinese developers have rapidly expanded their capabilities in antibody engineering, clinical development and translational research.

“This agreement brings together best-in-industry expertise of Pfizer and Innovent to advance novel cancer medicines to patients at a global scale,” said Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) at Innovent.

“By leveraging both companies’ complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide.”

Jeff Legos, Chief Oncology Officer at Pfizer, said the collaboration aligned with the company’s broader strategy to strengthen its oncology pipeline through external innovation partnerships.

“This collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting,” Legos said.

The deal further strengthens Pfizer’s oncology portfolio, which has increasingly focused on ADCs and immune-engaging biologics as the company seeks to build on recent cancer franchise growth. Industry observers note that the collaboration also highlights the continuing globalisation of oncology R&D, with Chinese biotech companies increasingly serving as sources of early-stage innovation for large pharmaceutical companies.

Founded in 2011, Innovent has grown into one of China’s leading biopharmaceutical companies, with 18 marketed products and multiple late-stage oncology and immunology programmes. The company already maintains partnerships with several multinational healthcare groups, including Eli Lilly, Roche, Takeda and Sanofi.

The transaction remains subject to customary regulatory approvals.